Equity Profile

PTCT

PTC Therapeutics, Inc.

Health CareBiotechnology$5.9B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

PTC Therapeutics Beats on EPS, Stock Down 3.12%

Metric	Actual	Expected	Surprise
EPS	$-0.03	$-0.44	+93.35%
Revenue	—	$233M	—

management commentary, guidance changes, and full analysis available with Pro.

PTC Therapeutics Beats on EPS, Stock Down 3.12%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.03	$-0.44	+93.35%
Revenue	—	$233M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

PTC Therapeutics reported a smaller-than-expected loss per share, which is a positive surprise for investors. However, the stock fell by 3.12% in reaction, indicating that investors may have been anticipating more robust revenue figures. The lack of revenue reporting and guidance may have contributed to the negative stock movement.

Company Snapshot

PTC Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-0.44

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$233M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

PTC Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases. Operating in the health care sector, its work is crucial as it addresses unmet medical needs and aims to improve the quality of life for patients with serious conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+101.20%

Avg Stock Reaction

-1.79%

Last Quarter Recap

In the last quarter, PTC Therapeutics reported an EPS of $-1.67, significantly missing analyst expectations. The stock reacted positively, gaining 1.41% the following day despite the disappointing results.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect PTC Therapeutics to report a loss of $0.44 per share on revenues of $233 million. Given the company's history of earnings surprises, there is a mix of optimism and caution in the market.

Bull Case

If PTC Therapeutics can exceed revenue expectations and demonstrate strong demand for its products, it could lead to a positive reassessment of the company's growth potential.

Bear Case

Conversely, if the company fails to meet revenue expectations or shows continued losses, it could raise concerns about its financial health and future viability.

Key Metrics to Watch

EPS

$-0.44

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$233M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the actual revenue number be compared to the consensus of $233 million?

Revenue is critical for assessing the company's growth trajectory and market demand for its products.

How does management plan to address the significant EPS loss of $-0.44?

Investors will be keen to hear about strategies to improve profitability and manage costs moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth due to recent product launches that have not yet fully impacted sales figures.

Supporting Evidence

The company's historical EPS surprise rate is 88%, suggesting a tendency to outperform expectations.

Options are pricing in a larger move than the stock has historically experienced, indicating potential for a surprise.

Recent insider selling may signal a lack of confidence in the near-term outlook, which could be misinterpreted by the market.

Key Risk

If revenue comes in below $164 million, it could invalidate the optimistic growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the backdrop of recent earnings surprises and historical performance.

Bull Confirmed If

Revenue exceeding $233 million would indicate strong demand and growth potential.

Bear Confirmed If

Revenue significantly below $164 million could raise serious concerns about the company's future.

Pre-Earnings Positioning

Options Market

Implied Move

±13.45%

Historical Avg

±2.6%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±13.5% while PTCT has averaged ±2.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

39.0%

Calls (46K)P/C Ratio: 0.02Puts (500)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.9%, with a raw directional average of +0.3% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$202,093.50

2,850 sh

1 insider

Net

$202,093.50

Net selling

Most Active Insiders· 1 open-market trade

CHIEF EXECUTIVE OFFICERKlein Matthew B.
$202,093.50

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If PTC Therapeutics beats expectations, history suggests the stock could see a positive reaction, potentially around a 2.36% increase.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a decline, with historical patterns indicating an average drop of around 1.41%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies to improve EPS.
3Insights into market demand for existing therapies and pipeline products.
4Guidance on future revenue expectations and any changes to long-term goals.
5Responses to analyst questions regarding recent insider selling and its implications.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

FANGReported

Diamondback Energy, Inc.

RecapView

May4

OSISReported

Company Snapshot

PTC Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-0.44

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$233M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+101.20%

Avg Stock Reaction

-1.79%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If PTC Therapeutics can exceed revenue expectations and demonstrate strong demand for its products, it could lead to a positive reassessment of the company's growth potential.

Bear Case

Conversely, if the company fails to meet revenue expectations or shows continued losses, it could raise concerns about its financial health and future viability.

Key Metrics to Watch

EPS

$-0.44

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$233M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the actual revenue number be compared to the consensus of $233 million?

Revenue is critical for assessing the company's growth trajectory and market demand for its products.

How does management plan to address the significant EPS loss of $-0.44?

Investors will be keen to hear about strategies to improve profitability and manage costs moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth due to recent product launches that have not yet fully impacted sales figures.

Supporting Evidence

The company's historical EPS surprise rate is 88%, suggesting a tendency to outperform expectations.

Options are pricing in a larger move than the stock has historically experienced, indicating potential for a surprise.

Recent insider selling may signal a lack of confidence in the near-term outlook, which could be misinterpreted by the market.

Key Risk

If revenue comes in below $164 million, it could invalidate the optimistic growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the backdrop of recent earnings surprises and historical performance.

Bull Confirmed If

Revenue exceeding $233 million would indicate strong demand and growth potential.

Bear Confirmed If

Revenue significantly below $164 million could raise serious concerns about the company's future.

Pre-Earnings Positioning

Options Market

Implied Move

±13.45%

Historical Avg

±2.6%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±13.5% while PTCT has averaged ±2.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

39.0%

Calls (46K)P/C Ratio: 0.02Puts (500)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.9%, with a raw directional average of +0.3% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$202,093.50

2,850 sh

1 insider

Net

$202,093.50

Net selling

Most Active Insiders· 1 open-market trade

CHIEF EXECUTIVE OFFICERKlein Matthew B.
$202,093.50

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If PTC Therapeutics beats expectations, history suggests the stock could see a positive reaction, potentially around a 2.36% increase.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on earnings could lead to a decline, with historical patterns indicating an average drop of around 1.41%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies to improve EPS.
3Insights into market demand for existing therapies and pipeline products.
4Guidance on future revenue expectations and any changes to long-term goals.
5Responses to analyst questions regarding recent insider selling and its implications.